|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, June 16, 2018 ) This report studies the global RNAi for Therapeutic market size, industry status and forecast, competition landscape and growth opportunity. This research report categorizes the global RNAi for Therapeutic market by companies, region, type and end-use industry.
RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression.
RNAi for Therapeutic is in the development stage and there is no use in the market. The fastest research is Clinical phrase III, Such as QP1-1007, QO1-1002 of Quark Pharmaceuticals. The major technology of RNAi for Therapeutic is siRNA, miRNA and shRNA. SiRNA technology is the most popular, with the expenses market share of 85%, following SiRNA, miRNA is the second of 16% expenses market share in 2015.
At present, global expenses concentrates in US and Europe, US takes 80% market share and Europe takes 5% market share. There is A Few R & D Company in the world and the market concentration is high. The top5 (expenses in RNAi for Therapeutic) companies are Alnylam Pharmaceuticals, Arrowhead, Dicerna Pharmaceuticals, Gradalis, miRagen Therapeutics. The five companies occupy about 83% of the market share.
In 2017, the global RNAi for Therapeutic market size was 990 million US$ and it is expected to reach 5200 million US$ by the end of 2025, with a CAGR of 23.1% during 2018-2025.
This report studies the global RNAi for Therapeutic market, analyzes and researches the RNAi for Therapeutic development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like
Alnylam Pharmaceuticals
Arbutus Biopharma (Tekmira)
Arrowhead
Dicerna Pharmaceuticals
Mirna Therapeutics
Quark Pharmaceuticals
RXi Pharmaceuticals
Silence Therapeutics
Benitec Biopharma
miRagen Therapeutics
Sylentis
Gradalis
Sirnaomics
Silenseed
FREE | sample of report @ http://www.reportsweb.com/inquiry&RW00012075218/sample
Market segment by Type, the product can be split into
siRNA
miRNA
shRNA
Market segment by Application, split into
Cancer
Cardiovascular
HBV
Other
Browse Complete Report @ http://www.reportsweb.com/global-rnai-for-therapeutic-market-size-status-and-forecast-2018-2025
The study objectives of this report are:
To study and forecast the market size of RNAi for Therapeutic in global market.
To analyze the global key players, SWOT analysis, value and global market share for top players.
To define, describe and forecast the market by type, end use and region.
To analyze and compare the market status and forecast between China and major regions, namely, United States, Europe, China, Japan, Southeast Asia, India and Rest of World.
To analyze the global key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends and factors driving or inhibiting the market growth.
To analyze the opportunities in the market for stakeholders by identifying the high growth segments.
To strategically analyze each submarket with respect to individual growth trend and their contribution to the market
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
To strategically profile the key players and comprehensively analyze their growth strategies.
Ask for Discount on Report @ http://www.reportsweb.com/inquiry&RW00012075218/discount
Table of Content
Global RNAi for Therapeutic Market Size, Status and Forecast 2025
1 Industry Overview of RNAi for Therapeutic
2 Global RNAi for Therapeutic Competition Analysis by Players
3 Company (Top Players) Profiles
3.1 Alnylam Pharmaceuticals
3.1.1 Company Profile
3.1.2 Main Business/Business Overview
3.1.3 Products, Services and Solutions
3.1.4 RNAi for Therapeutic Revenue (Million USD) (2013-2018)
3.2 Arbutus Biopharma (Tekmira)
3.2.1 Company Profile
3.2.2 Main Business/Business Overview
3.2.3 Products, Services and Solutions
3.2.4 RNAi for Therapeutic Revenue (Million USD) (2013-2018)
3.3 Arrowhead
3.3.1 Company Profile
3.3.2 Main Business/Business Overview
3.3.3 Products, Services and Solutions
3.3.4 RNAi for Therapeutic Revenue (Million USD) (2013-2018)
4 Global RNAi for Therapeutic Market Size by Type and Application (2013-2018)
5 United States RNAi for Therapeutic Development Status and Outlook
6 EU RNAi for Therapeutic Development Status and Outlook
7 Japan RNAi for Therapeutic Development Status and Outlook
8 China RNAi for Therapeutic Development Status and Outlook
9 India RNAi for Therapeutic Development Status and Outlook
10 Southeast Asia RNAi for Therapeutic Development Status and Outlook
11 Market Forecast by Regions, Type and Application (2018-2025)
12 RNAi for Therapeutic Market Dynamics
13 Market Effect Factors Analysis
Place Direct Purchase order For Complete report @ http://www.reportsweb.com/buy&RW00012075218/buy/3300
ReportsWeb.com
Rajat Sahni
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
